Related Experiment Video
Updated: Jul 13, 2025

Intrarenal Injection of Escherichia coli in a Rat Model of Pyelonephritis
Published on: July 18, 2017
Nephrotoxicity caused by colistin use in ICU: a single centre experience
Isa Kilic1, Yavuz Ayar2, İlkay Ceylan3
1Department of Anesthesiology and Intensive Care, Ministry of Health, Bursa City Hospital , Bursa, Turkey. kilicisaicu@gmail.com.
Background:
We aimed to determine the risk factors that may be associated with colistin-induced acute kidney injury (AKI) to promote the safer use of colistin in the treatment of nosocomial infections caused by multidrug-resistant Gram-negative bacteria in intensive care units.
Materials And Methods:
This retrospective observational study was conducted among adult patients who received a minimum of 48 h of intravenous colistin from January 2020 to December 2020 at the intensive care unit of a tertiary care hospital. AKI diagnosis and staging were made based on the Kidney Disease Improving Global Outcome Criteria.
Results:
Of 148 patients who received intravenous colistin at a daily dose of 9 million IU, 54 (36%) developed AKI. In the univariate analysis, age, Charlson comorbidity index, APACHE II score, duration of colistin treatment, basal creatinine level, use of vasopressors, and vancomycin were significantly associated with AKI (p < 0.05). The multivariate analysis revealed that the independent predictor of AKI was the use of vasopressors (OR: 3.14; 95% confidence interval: 1.39-97.07; p = 0.06).
Conclusion:
The use of vasopressors in critically ill patients was independently associated with AKI developing during colistin treatment.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury I: Introduction
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Pyelonephritis II: Diagnostic Studies and Management
Cardiac Catheterization I: Pre-Procedure Overview

